#USA #Veeva Systems #Clinical Trials #Pleasanton #Study Builder Agent

Veeva Systems Unveils the Study Builder Agent

In a groundbreaking announcement, Veeva Systems (NYSE: VEEV) has introduced the Veeva Study Builder Agent, a state-of-the-art AI solution designed to revolutionize the configuration of clinical studies. This innovative tool promises to streamline the process, enabling researchers to set up their studies in a mere day — a remarkable improvement that could significantly expedite the clinical trial landscape.

What is the Veeva Study Builder Agent?

The Veeva Study Builder Agent leverages artificial intelligence to configure Veeva's Electronic Data Capture (EDC) and Data Quality System (DQS) based directly on a study protocol. By reusing an organization’s existing standards and incorporating the CDISC Unified Study Definitions Model (USDM), the agent ensures a more rapid and consistent creation of studies. This capability is crucial for organizations aiming to maintain high standards while minimizing variability in their study configurations.

Features and Benefits

Among its many features, the Study Builder Agent automates the configuration of EDC forms, visits, and verification rules. It even includes automated testing, which generates test data, thus reducing the burden on data management teams. As it builds upon predefined organizational standards, it is designed to minimize deviations, thereby boosting productivity and ensuring the outcomes are audit-ready from the outset.

Drew Garty, Veeva’s Chief Technology Officer for Clinical Data, stated, "With the Veeva Study Builder Agent, high-quality studies can be created much faster. We are committed to innovations that simplify, standardize, and connect clinical trials, and the Study Builder Agent is a significant step toward realizing this vision."

Availability

The Veeva Study Builder Agent is set to become available for early adopters starting in December 2026. Importantly, it will function as part of the existing EDC framework without requiring an additional license. Users will access it through a Claude Cowork-Plugin, which can be easily installed via a GitHub repository managed by Veeva.

Upcoming Event

To learn more about Veeva’s comprehensive clinical data solutions—including EDC, DQS, and eCOA—attendees can visit the Veeva RD and Quality Summit scheduled for October 20-21 in Boston. This event is tailored exclusively for professionals in the life sciences sector, promising rich insights into enhancing study efficacy and data quality.

Conclusion

Veeva Systems continues to push the boundaries of technology in clinical research. With the introduction of the Study Builder Agent, it looks set to transform how clinical trials are conducted, making them faster and more efficient. This initiative aligns with the company’s dedication to fostering innovation across the life sciences industry, ensuring that stakeholders can adapt to the increasingly complex demands of clinical studies.

For more information about Veeva Systems and their innovative solutions, visit veeva.com.